Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB26FNMNA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $9,284
Award facts
- Contract value 100% obligated
- $9,284.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $9,284.40 to DMS Pharmaceutical Group Inc. for XOLAIR 150 mg/ml syringes on October 23, 2025, with an ultimate completion date of November 14, 2025. This firm fixed-price delivery order was awarded without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal pharmaceutical procurement. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected to supply this biologic immunosuppressant medication to support Department of Defense medical supply requirements.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499,999,999 ceiling value extending through December 31, 2036. The broader PPV-G GEN V acquisition strategy, valued at $30.3 billion, establishes multiple regional prime vendor contractors to supply comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance on numerous delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FNMNA?
SPE2DB26FNMNA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 23, 2025.
How much is contract SPE2DB26FNMNA worth?
The government has obligated $9,284 on SPE2DB26FNMNA.
Is contract SPE2DB26FNMNA an order under another contract?
Yes. SPE2DB26FNMNA is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMNA competed?
The extent of competition for SPE2DB26FNMNA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award